Industry & Policy News

[Ocular Therapeutix, Inc.] Ocular Therapeutix, Inc. announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration (wet AMD).

[ContraFect, Corp.] ContraFect, Corp. announced that the US FDA completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, and concluded that the company may proceed with its Phase I clinical study.

[Fierce Biotech] Ichnos Sciences has finally found a buyer for its OX40 eczema program. Astria Therapeutics has taken the other side of the deal, paying $15 million upfront to secure a spot at the back of a race led by Amgen and Sanofi.

[Nature] Researchers have created the largest atlas of human brain cells so far, revealing more than 3,000 cell types — many of which are new to science.

[Kyverna Therapeutics] This is the third IND clearance for KYV-101, a novel, fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases.

[UT Health San Antonio] The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announced the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer.